Work in Progress

Three years ago, Enzon Pharmaceuticals was in the doldrums. A merger with NPS Pharmaceuticals had fallen apart the previous year. Its research pipeline was full, but the ultimate sales potential of the lineup was questionable. Employee morale was low.
NJ.com